Literature DB >> 9531043

Changes of prothrombin fragment 1+2 (F 1+2) as a function of increasing intensity of oral anticoagulation--considerations on the suitability of F 1+2 to monitor oral anticoagulant treatment.

A Tripodi1, M Cattaneo, A Molteni, B M Cesana, P M Mannucci.   

Abstract

Plasma F 1+2 levels, the activation peptide originating from the factor Xa-mediated activation of prothrombin, increase in many clinical conditions associated with hypercoagulability and decrease in patients on oral anticoagulant treatment (OAT). However. the usefulness of F 1+2 measurement to monitor OAT has not yet been investigated in clinical studies. Before those studies are attempted, the plausibility of its implementation in the laboratory control of OAT should be evaluated. In this respect, a thorough investigation of the pattern of changes of F 1+2 as a function of increased intensity of anticoagulation expressed as International Normalized Ratio is essential. One hundred and thirty-two patients on long-term warfarin treatment were recruited to cover 8 ranges of anticoagulation from < 1.5 to 9.0 INR. F 1+2 was measured in batch on frozen plasma and INR was determined on fresh plasma. The relationship of F 1+2 vs. INR showed a hyperbolic pattern with F 1+2 levels decreasing progressively and significantly as a function of increasing INR up to 3.0. A further decrease in F 1+2 levels observed at INR up to 4.0 was not statistically significant. At INR greater than 4.0, F 1+2 reached a plateau, with mean levels not significantly different for patients at increasing INR up to 9.0. Since the risk of bleeding increases at INR greater than 4.5, our results suggest that F 1+2 is of little value to assess the hemorrhagic risk in patients on OAT.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9531043

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  6 in total

1.  The hemostatic effects of warfarin titration in post CABG patients in comparison to placebo treatment.

Authors:  J M Walenga; D Hoppensteadt; R Pifarré; N L Fox; S Forman; D B Hunninghake; L Campeau; J A Herd; B J Hoogwerf; A Hickey; J L Probstfield; M L Terrin
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

2.  Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects.

Authors:  Pascale Gaussem; M Dubar; B le Bonniec; I Richard-Lordereau; R Jochemsen; M Aiach
Journal:  Br J Clin Pharmacol       Date:  2002-02       Impact factor: 4.335

3.  Hemostatic effects of 1 mg daily warfarin on post CABG patients. Post CABG Studies Investigators.

Authors:  J M Walenga; D Hoppensteadt; R Pifarré; M D Cressman; D B Hunninghake; N L Fox; M L Terrin; J L Probstfield
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

4.  Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.

Authors:  H Cohen; C J Doré; S Clawson; B J Hunt; D Isenberg; M Khamashta; N Muirhead
Journal:  Lupus       Date:  2015-05-04       Impact factor: 2.911

5.  Effects of anticoagulation on markers of activation of clotting following major orthopedic surgery.

Authors:  M M Bern; D Hazel; D T Reilly; D M Adcock; L Hou
Journal:  Int J Lab Hematol       Date:  2015-05-15       Impact factor: 2.877

6.  Multivariate relationships between international normalized ratio and vitamin K-dependent coagulation-derived parameters in normal healthy donors and oral anticoagulant therapy patients.

Authors:  Cezary Watala; Jacek Golanski; Przemyslaw Kardas
Journal:  Thromb J       Date:  2003-11-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.